Yes, every pharmaceutical facility should have a written contamination control strategy. Regulatory frameworks including EU GMP Annex 1 (revised in 2022) and FDA guidance now explicitly expect manufacturers to document a holistic, risk-based approach to contamination prevention rather than relying on informal or reactive practices. The questions below unpack what a robust written strategy looks like, what it must contain, and how to keep it current.
What does a written contamination control strategy actually include?
A written contamination control strategy is a formal, documented framework that identifies contamination risks within a pharmaceutical facility, defines the controls in place to manage those risks, and provides evidence that those controls are effective. It covers people, processes, equipment, environment, and materials as potential contamination sources, and it links each identified risk to a specific, validated mitigation measure.
In practical terms, a well-structured written CCS will typically address:
- The facility layout, including the classification of cleanroom zones and controlled areas
- Personnel flows, gowning requirements, and hygiene protocols
- Equipment qualification, cleaning validation, and maintenance schedules
- Environmental monitoring programmes and alert and action limits
- Material and component entry controls, including decontamination procedures
- Floor-level and surface contamination controls at critical entry points
- Procedures for investigating and responding to out-of-specification results
- Roles, responsibilities, and training requirements for all personnel
The strategy is not a single procedure document. It is an overarching document that ties together all contamination-related procedures, risk assessments, and monitoring data into a coherent, auditable whole.
Is a written contamination control strategy a regulatory requirement?
For sterile medicinal product manufacturers operating under EU GMP, a written contamination control strategy is a direct regulatory requirement. The revised EU GMP Annex 1, which came into full effect in August 2023, explicitly requires manufacturers to prepare and maintain a CCS that demonstrates a thorough understanding of contamination risks and the controls used to manage them. While FDA regulations do not use the term “contamination control strategy” verbatim, the underlying expectation of documented, risk-based contamination management is embedded throughout 21 CFR Parts 210 and 211.
Beyond sterile manufacturing, the broader GMP expectation across pharmaceutical production is that contamination risks are identified, assessed, and controlled in a documented and systematic way. Facilities producing non-sterile products are not exempt from this logic. Regulatory inspectors across major markets increasingly expect to see a written strategy that demonstrates proactive rather than reactive contamination management.
Failing to maintain a documented CCS exposes a facility to significant audit risk. Inspectors look for evidence that contamination controls are not merely in place but are understood, monitored, and continuously improved. A verbal or informal approach, however well-intentioned, will not satisfy that expectation.
What are the key elements of an effective contamination control strategy?
An effective pharmaceutical contamination control strategy is built on risk assessment, validated controls, and ongoing monitoring. The key elements are those that together demonstrate a facility understands where contamination can enter or arise, has implemented proportionate measures to prevent it, and can prove those measures are working.
Risk assessment and contamination source identification
The strategy must begin with a systematic identification of all potential contamination sources. This includes microbial, particulate, chemical, and cross-contamination risks. A quality risk management approach, typically using tools such as FMEA or risk ranking matrices, helps prioritise controls according to the severity and probability of each identified risk. Without this foundation, the rest of the strategy lacks scientific justification.
Validated controls and monitoring evidence
Each identified risk must be linked to a specific, validated control. Controls should be supported by qualification data, cleaning validation studies, or environmental monitoring trends that demonstrate their effectiveness. The strategy should also define how monitoring data are reviewed, what triggers an investigation, and how corrective actions are documented and closed out. This creates the audit trail that regulators expect to see.
How does floor-level contamination fit into a pharmaceutical CCS?
Floor-level contamination is a critical and often underestimated risk category within any pharmaceutical contamination control strategy. Industry experience consistently shows that the majority of particulate and microbial contamination entering a controlled environment is carried in at floor level, primarily on footwear and wheeled equipment. A robust CCS must therefore include specific, validated controls at every pedestrian and wheeled-traffic entry point into classified zones.
Common floor-level controls include sticky mats, shoe covers, footbaths, and reusable polymeric contamination control mats. Each has a different performance profile, and the CCS should document the rationale for the chosen solution, including any comparative data or validation evidence that supports the selection. Sticky mats, for example, degrade rapidly with use and offer inconsistent capture performance as layers are peeled away. A reusable polymeric mat system, by contrast, maintains consistent capture performance across its operational lifespan and can be validated as part of the facility’s environmental monitoring programme.
The CCS should specify where floor-level controls are deployed, the cleaning and maintenance schedule for each control, and how their performance is verified. Entry points to gowning rooms, airlocks, cleanroom corridors, and production areas all represent critical locations that the strategy must address explicitly.
What’s the difference between a contamination control strategy and a contamination control plan?
A contamination control strategy is a high-level, facility-wide document that defines the overall approach to contamination risk management, including the philosophy, risk assessment methodology, and the framework of controls across all contamination types and zones. A contamination control plan is typically more operational and specific, describing the detailed procedures, schedules, and responsibilities for implementing particular controls within a defined area or process.
In practical terms, the CCS is the strategic document that would be reviewed during a regulatory inspection to demonstrate that contamination management is systematic and risk-based. A contamination control plan might sit beneath it as a supporting document, detailing how specific controls are executed on the floor day to day. The two are complementary rather than interchangeable.
Some facilities use the terms differently or combine them into a single document structure. What matters from a regulatory perspective is not the label but the content: inspectors want to see that contamination risks have been identified, that controls are proportionate and validated, and that the whole system is monitored and reviewed. Whether that evidence lives in one document or several is a matter of facility preference and document management structure.
How often should a pharmaceutical contamination control strategy be reviewed?
A pharmaceutical contamination control strategy should be reviewed at least annually as a minimum, and additionally whenever a significant change occurs that could affect contamination risk. Periodic review ensures the strategy remains current, reflects the actual state of the facility, and incorporates lessons learned from environmental monitoring data, deviation investigations, and audit findings.
Triggers for an unscheduled review include:
- Facility modifications, including new cleanroom zones, revised layouts, or changes to HVAC systems
- Introduction of new products, processes, or equipment
- Changes to personnel flows or gowning procedures
- Recurring environmental monitoring excursions or contamination events
- Regulatory inspection findings or updated guidance from health authorities
- Changes to cleaning agents, disinfectants, or contamination control materials
The review process itself should be documented, with a record of what was assessed, what changes were made, and who approved the revised strategy. A CCS that has not been reviewed or updated in several years is a red flag for inspectors, as it suggests the facility’s contamination management approach may have drifted from its documented controls.
How Dycem supports your pharmaceutical contamination control strategy
Building a defensible, audit-ready contamination control strategy requires the right physical controls at critical entry points, not just the right documentation. Dycem’s reusable contamination control mats are engineered to deliver consistent, validated particulate capture performance at every floor-level entry point in your facility, supporting the evidence base your CCS needs.
Dycem’s contamination control mat range includes solutions designed for every facility zone and traffic type:
- Dycem CleanZone for pedestrian and light-wheeled traffic at cleanroom entrances, gowning rooms, and airlocks
- Dycem WorkZone for heavy-wheeled traffic including forklifts and pallet trucks in production and logistics areas
- Dycem Floating Mats for flexible, repositionable coverage across variable or temporary controlled zones
- Dycem Bench Mats and Access Panels for workstation-level contamination control beyond the floor
All Dycem mats are reusable, built with integrated Biomaster antimicrobial protection, and manufactured to ISO 9001 and 14001 standards, making them a sustainable and compliant alternative to disposable sticky mats. With a lifespan exceeding three years and contamination specialists available to support your facility assessment, Dycem helps you build floor-level contamination control that stands up to regulatory scrutiny. Contact Dycem to arrange a free site survey and find out how Dycem can strengthen your contamination control strategy.